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Thyroid function and ischemic 
heart disease: a Mendelian 
randomization study
Jie V. Zhao1 & C. Mary Schooling  1,2
To clarify the role of thyroid function in ischemic heart disease (IHD) we assessed IHD risk and risk 
factors according to genetically predicted thyroid stimulating hormone (TSH), free thyroxine (FT4) 
and thyroid peroxidase antibody (TPOAb) positivity. Separate-sample instrumental variable analysis 
with genetic instruments (Mendelian randomization) was used in an extensively genotyped case 
(n = 64,374)-control (n = 130,681) study, CARDIoGRAMplusC4D. Associations with lipids, diabetes 
and adiposity were assessed using the Global Lipids Genetics Consortium Results (n = 196,475), the 
DIAbetes Genetics Replication And Meta-analysis case (n = 34,380)-control (n = 114,981) study, and 
the Genetic Investigation of ANthropometric Traits (body mass index in 152,893 men and 171,977 
women, waist-hip ratio in 93,480 men and 116,741 women). Genetically predicted thyroid function was 
not associated with IHD (odds ratio (OR) per standard deviation for TSH 1.05, 95% confidence interval 
(CI) 0.97 to 1.12; for FT4 1.01, 95% CI 0.91 to 1.12; for TPOAb positivity 1.10, 95% CI 0.83 to 1.46) or 
after Bonferroni correction with risk factors, except for an inverse association of FT4 with low-density 
lipoprotein-cholesterol. The associations were generally robust to sensitivity analyses using a weighted 
median method and MR Egger. This novel study provides little indication that TSH, FT4 or TPOAb 
positivity affects IHD, despite potential effects on its risk factors.
Cardiovascular disease (CVD) is the leading cause of mortality globally1. Despite substantial progress in preven-
tion and control, the etiology of CVD is not completely understood2, as evidenced by failures of new treatments3. 
Moreover, men have substantially higher rates of ischemic heart disease (IHD) than women at the same level of 
established risk factors2, generating the possibility of discovering new potentially modifiable risk factors, possibly 
related to sex or gender, for a leading cause of death. Evolutionary biology suggests growth and reproduction 
trade-off against longevity4. Increasing genetic evidence in humans is emerging, indicating that lower growth hor-
mone and/or insulin like growth factor (IGF) are associated with longer life and lower risk of major chronic dis-
eases5, 6. Across the animal kingdom it is well-established that suppressing the reproductive axis increases lifespan, 
and promoting the reproductive axis reduces lifespan7, 8. However, the relation of the reproductive axis to lifespan 
has been little investigated in humans9. Estrogen administration has been shown to have no benefit for CVD in 
men10 or women11, while the role of testosterone remains controversial12, although both Health Canada and the 
Food and Drug Administration in the US have warned of the cardiovascular risk of testosterone in men13, 14, 
and testosterone increases the hallmark of atherosclerosis, i.e., coronary artery plaque volume15. The hypotha-
lamic–pituitary–thyroid axis interacts with the hypothalamic–pituitary–gonadal axis16. Thyroid hormones are 
also involved in testicular development in animals17. In humans, both overt and subclinical thyroid dysfunction, 
especially the former, are associated with higher risk of CVD events18–20. As such, thyroid function might play a 
role in CVD.
Clinically, thyroid function is assessed by measuring serum thyroid stimulating hormone (TSH) and free 
thyroxine (FT4). TSH is a key regulator of thyroid function, which promotes the synthesis and secretion of thy-
roid hormones, i.e., thyroxine and triiodothyronine21. FT4 is the active form of thyroxine. Thyroid peroxidase 
antibodies (TPOAbs) also play a key role in the synthesis of thyroid hormones; TPOAb positivity is associ-
ated with higher risk of autoimmune hyperthyroidism22. Observationally, higher TSH, even within the normal 
range, is associated with higher risk of CVD events23. In some, but not all observational studies, higher TSH 
and lower FT4 are associated with unhealthier lipids and glucose metabolism, such as an association of higher 
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TSH with higher total cholesterol24, higher low-density lipoprotein (LDL)-cholesterol24, lower high-density 
lipoprotein (HDL)-cholesterol25, and higher HbA1c25, and of higher FT4 with lower LDL-cholesterol26, 
higher HDL-cholesterol27, and lower fasting glucose26. However, some studies have found no association27–31. 
Observationally, people who are TPOAb-positive have higher TSH and faster carotid intima media thickness 
(cIMT) progression32, however, in another study, cardiovascular risk associated with subclinical hypothyroidism 
did not differ by TPOAb status33. A meta-analysis of cohort studies has shown that higher and lower TSH are both 
associated with higher risk of CVD events34. In several randomized controlled trials (RCTs), levothyroxine, the 
artificial thyroxine which lowers TSH via negative feedback loop, exerts beneficial effects on CVD risk factors35–39. 
For example, lowering TSH into the normal range with levothyroxine decreases brachial-ankle pulse wave veloc-
ity35, total cholesterol36–38, LDL-cholesterol36–38, apolipoprotein B38, and cIMT37. However, in the Coronary Drug 
Project, dextrothyroxine, the D-type isomer of levothyroxine, which is also a TSH-lowering agent, reduced cho-
lesterol but increased the risk of CVD, so that the trial was discontinued because of excess risk40. However, dex-
trothyroxine and levothyroxine have quite different biological activity41, 42. As such, the role of thyroid function 
as a target of intervention in CVD is unclear. Two RCTs to examine the effect of levothyroxine on CVD are being 
proposed43, 44, which ideally should be preceded by genetic validation of role of thyroid function in CVD.
Mendelian randomization (MR) provides a means of assessing genetic validity, by examining whether people 
with genetically different levels of TSH, FT4 and TPOAb positivity have higher or lower risk of IHD. MR uses 
genetic endowment randomly allocated at conception as instrument to predict exposures, analogous to the rand-
omization in RCTs, as such MR is an increasingly popular means of obtaining unconfounded estimates45. Thyroid 
function has high heritability (up to 65% for TSH and FT4 in twin and family studies46), which also provides a 
good opportunity to apply MR. To clarify the role of thyroid function, we assessed the associations of genetically 
predicted TSH, FT4 and TPOAb positivity with coronary artery disease/myocardial infarction (CAD/MI) using 
instrumental variable analysis with genetic instruments, i.e., MR, in large case-control studies with extensive gen-
otyping. We similarly assessed the associations with established CVD risk factors, including lipids, diabetes and 
adiposity to identify if any associations with IHD were independent of these risk factors.
Results
We identified 34 single nucleotide polymorphisms (SNPs) in the genes PDE8B, PDE10A, CAPZB, MAF, VEGFA, 
NR3C2, IGFBP5, SOX9, NFIA, FGF7, PRDM11, MIR1179, INSR, ABO, ITPK1, NRG1, MBIP, SASH1, GLIS3, 
IGFBP2, SYN2, FOXE1, and GNAS for TSH47–49, 7 SNPs in the genes DIO1, LHX3, FOXE1, AADAT and B4GALT6 
for FT4 in men and women47, 49, and 3 SNPs in the genes TPO, MAGI3 and KALRN for TPOAb positivity22. Eight 
SNPs (rs12410532, rs28435578, rs2046045, rs6923866, rs2396084, rs3008034, rs116552240, and rs17767742) 
for TSH were excluded because of linkage disequilibrium (LD) with other SNPs for TSH, i.e., rs10799824, 
rs10032216, rs6885099, rs11755845, rs9472138, rs753760, rs657152, and rs3813582. Three SNPs (rs13015993 
in IGFBP5, rs7568039 in IGFBP2 and rs657152 in ABO) were excluded from the analysis of TSH with CAD/
MI due to potential pleiotropy. Rs13015993 in IGFBP5 and rs7568039 in IGFBP2 might be associated with 
CAD/MI other than via TSH50 because associations with CAD were suggested by the MR Catalogue (p value 
1.73 × 10−4 for rs13015993; 1.40 × 10−4 for rs7568039). Moreover, the expression of IGFBP2 and IGFBP5 relates 
to the growth hormone/IGF system47, which is associated with risk of major chronic diseases in genetic studies5, 
6. Correspondingly, calorie restriction in a clinical trial also lowered IGF-1 and CVD risk factors51. Rs657152 is in 
ABO, a gene strongly associated with IHD for reasons that are not entirely clear but may be unrelated to TSH52. 
Three SNPs were not in CARDIoGRAMplusC4D Metabochip and 1 SNP was not in CARDIoGRAMplusC4D 
1000 Genomes, and no proxies could be found (Supplemental Table 1). As such, 20 SNPs (mean F statistic 59.3) 
were used for TSH and CAD/MI in CARDIoGRAMplusC4D Metabochip and 22 SNPs (mean F statistic 58.3) 
in CARDIoGRAMplusC4D 1000 Genomes. Two FT4-related SNPs (rs11103377 and rs7694879) were excluded 
due to LD with rs7860634 and rs11726248 respectively. None were excluded due to pleiotropic associations 
with CAD/MI, so 5 SNPs (mean F statistic 61.4) were used for FT4. One TPOAb positivity SNP (rs653178) was 
excluded due to pleiotropic associations with blood pressure and CAD/MI50, 53, so 2 SNPs (mean F statistic 33.4) 
were used for TPOAb positivity and CAD/MI. Supplemental Table 1 gives the genetic associations with TSH, FT4 
and TPOAb positivity, and the information for potential pleiotropy. Sex-specific SNPs were used in sex-specific 
analysis of adiposity in GIANT. For TSH, 6 SNPs reached genome-wide significance in men and 7 SNPs reached 
genome-wide significance in women. Three SNPs (rs13015993, rs753760, and rs10519227) in men and 2 SNPs 
(rs753760 and rs9497965) in women were excluded due to pleiotropic associations with obesity (Supplemental 
Table 1), as such, 3 SNPs in men and 5 SNPs in women were used for TSH and adiposity (Supplemental Table 2). 
For FT4, 3 SNPs reached genome-wide significance in men and 3 SNPs reached genome-wide significance in 
women. None were excluded due to LD or pleiotropy (Supplemental Table 2).
Genetically predicted TSH, FT4 and TPOAb positivity were not associated with risk of CAD/MI when poten-
tially pleiotropic SNPs were excluded (Table 1 and Fig. 1). The associations of TSH and TPOAb positivity with 
IHD and MI in CARDIoGRAMplusC4D 1000 Genomes and the association of TPOAb positivity with IHD in 
CARDIoGRAMplusC4D Metabochip showed heterogeneity when potentially pleiotropic SNPs were included 
(Table 1). Most of the associations with lipid profile (LDL-cholesterol, HDL-cholesterol or triglycerides) or dia-
betes (Figs 2 and 3, and Supplemental Tables 3–5) were null, but we identified an association of higher genetically 
predicted FT4 with lower LDL-cholesterol (Fig. 3 and Supplemental Table 4) and an association of genetically 
predicted TPOAb positivity with lower HDL-cholesterol (Fig. 4 and Supplemental Table 5). Genetically pre-
dicted TSH and FT4 were also unrelated to body mass index (BMI) and wasit-hip ratio (WHR) in sex-specific 
analysis, but genetically predicted higher TSH was nominally associated with lower WHR in men (Figs 5, 6 
and Supplemental Tables 3 and 4). Most of the associations with glucose metabolism were null (Supplemental 
Figs 1, 2 and 3) but we identified an association of higher TSH with lower 2 hour glucose (Supplemental Fig. 1). 
These associations were generally robust to SNP selection, however, TPOAb positivity was associated with higher 
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risk of CAD/MI when including the SNP with potential pleiotropy (Table 1), and the association of TSH with 
WHR in men became null when including the SNPs with potential pleiotropy (Supplemental Table 3). These 
associations were also generally robust to different statistical methods, however, the associations of TSH with 
WHR in men and 2 hour glucose in men and women became null when using a weighted median estimator or 
MR Egger, and there was an inverse association of TSH with HOMA-b using MR Egger (Supplemental Table 3). 
Taking into account multiple comparisons, all the associations, except for the inverse association of FT4 with 
LDL-cholesterol, were null after Bonferroni correction (corrected p-value: 0.05/5 (traits considered)/3 (expo-
sures) = 0.003). The intercept from MR Egger for TSH and CAD/MI in CARDIoGRAMplusC4D Metabochip was 
smaller when including potentially pleiotropic SNPs, which might occur by chance, because we did not observe 
this in CARDIoGRAMplusC4D 1000 Genomes.
Discussion
Using MR to obtain unconfounded estimates, genetically predicted TSH, FT4 and TPOAb positivity were 
not associated with risk of CAD/MI, despite a positive association of TPOAb positivity with CAD/MI in 
CARDIoGRAMplusC4D Metabochip when including a potentially pleiotropic SNP. Most of the associations 
with CVD risk factors were null, but genetically predicted higher TSH was associated with lower WHR in 
men and lower 2 hour glucose in men and women, genetically predicted higher FT4 was associated with lower 
LDL-cholesterol and genetically predicted TPOAb positivity was associated with lower HDL-cholesterol. This 
novel study does not corroborate a role of TSH, FT4 or TPOAb positivity in CAD/MI, although it cannot rule out 
a potential role in CVD risk factors.
To our knowledge, our study is the first MR examining the effects of TSH, FT4 and TPOAb positivity on 
IHD and CVD risk factors. Taking advantage of large publicly-available genome-wide association stud-
ies (GWAS) and large case-control studies with extensive genotyping enabled us to conduct a well-powered 

















value† OR 95% CI
TSH
IHD Metabochip 20 IVW 1.05 0.97 to 1.12 21.7 22 1.07 0.997 to 1.14
28.5 (0.13)WM 1.05 0.94 to 1.16 (0.30) 1.06 0.95 to 1.18
MR Egger 1.02 0.94 to 1.10 0.05 1.07 0.98 to 1.16 0.63
IHD
1000 22 IVW 0.99 0.93 to 1.05 16.2 25 0.96 0.91 to 1.01 51.2
Genomes WM 1.004 0.93 to 1.09 (0.76) 0.95 0.88 to 1.03 (0.001)
MR Egger 0.99 0.93 to 1.05 0.93 0.97 0.88 to 1.06 0.68
MI
1000 22 IVW 1.005 0.94 to 1.07
14.5 (0.85)
25 0.98 0.92 to 1.04 53.4
Genomes WM 0.99 0.90 to 1.08 0.98 0.90 to 1.07 (0.001)




5 IVW 1.01 0.91 to 1.12
3.6 (0.47)
5 1.01 0.91 to 1.12 3.6 (0.47)
WM 1.02 0.89 to 1.17 1.02 0.89 to 1.17
MR Egger 1.04 0.71 to 1.50 0.88 1.04 0.71 to 1.50 0.88
IHD
1000 5 IVW 1.06 0.97 to 1.15
3.8 (0.44)
5 1.06 0.97 to 1.15 3.8 (0.44)
Genomes WM 1.07 0.96 to 1.20 1.07 0.96 to 1.20
MR Egger 1.36 0.87 to 2.13 0.26 1.36 0.87 to 2.13 0.26
MI
1000 5 IVW 1.06 0.96 to 1.17
3.9 (0.41)
5 1.06 0.96 to 1.17 3.9 (0.41)
Genomes WM 1.07 0.95 to 1.21 1.07 0.95 to 1.21
MR Egger 1.62 0.98 to 2.67 0.09 1.62 0.98 to 2.67 0.09
TPOAb 
positivity
IHD Metabochip 2 IVW 1.10 0.83 to 1.46
2.4 (0.12)
3 1.41 1.10 to 1.80
12.8 (0.002)
WM 1.11 0.82 to 1.51 1.61 1.02 to 2.56
IHD
1000 Genomes
2 IVW 0.95 0.79 to 1.13
0.05 (0.83)
3 1.07 0.91 to 1.26
18.4 (0.0001)
WM 0.95 0.78 to 1.14 0.95 0.79 to 1.16
MI
1000 Genomes
2 IVW 0.93 0.77 to 1.13
0.5 (0.49)
3 1.07 0.89 to 1.28
20.3 (<0.0001)
WM 0.93 0.75 to 1.15 0.96 0.77 to 1.19
Table 1. Associations per standard deviation (SD) thyroid-stimulating hormone (TSH), free thyroxine 
(FT4) and thyroid peroxidase antibody (TPOAb) positivity with IHD and MI, obtained from separate sample 
instrumental variable analysis in CARDIoGRAMplusC4D Metabochip and CARDIoGRAMplusC4D 1000 
Genomes, using different SNP selection and methods. OR, odds ratio; MI, myocardial infarction; CI, confidence 
interval; IVW, inverse variance weighting; TPOAb, thyroid peroxidase antibody; WM, weighted median 
method. *SNPs with potential pleiotropy for TSH: rs13015993, rs7568039 and rs657152; for TPOAb positivity: 
rs653178. No SNPs were identified to be with potential pleiotropy for FT4. †The intercept can be interpreted as 
an estimate of the average pleiotropic effect across the genetic variants where a corresponding p-value of <0.05 
indicates the presence of directional pleiotropy across the genetic variants included in the analyses. ‡ For TSH, 
rs12523579 was used as a proxy for rs2928167. For FT4, rs4799592 was used as a proxy for rs113107469 in 
CARDIoGRAMplusC4D Metabochip; rs4297160 was used as a proxy for rs7045138 in CARDIoGRAMplusC4D 
1000 Genomes.
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CARDIoGRAMplusC4D 1000 Genomes with 60,801 cases and 123,504 controls has 0.8 power to detect an odds 
ratio (OR) of about 1.04 per standard deviation (SD) increase in TSH at an R2 of ~0.14 and an OR of about 1.07 
per SD increase in FT4 at an R2 of ~0.0455. Our MR study design used separate samples, i.e., GWAS for the genetic 
associations with the exposures (TSH, FT4 and TPOAb positivity), and large case-control studies for the genetic 
associations with the outcomes. The samples were recruited from different studies, with a very small proportion 
(around 1–4%) of overlap between the GWAS for exposures22, 47, 48 and CARDIoGRAMplusC4D Metabochip and 
1000 Genomes50, 52. As such, this MR is less open to confounding than one sample MR, because any correlation of 
the genetic variants with unmeasured confounders in the samples with TSH, FT4 and TPOAb positivity are less 
likely to be replicated in the samples with the outcomes, due to the different data structures56.
Nevertheless, several limitations exist. First, MR requires stringent assumptions, i.e., the genetic instruments 
are associated with the exposure, are not associated with the outcomes other than via the relevant exposure (no 
pleiotropy) and no confounders of the associations of the genetic instruments with the outcomes exist45. To satisfy 
these conditions, we only selected SNPs strongly associated with TSH, FT4 and TPOAb positivity. Most SNPs are 
from genes functionally relevant to thyroid function, such as NFIA which interacts with thyroid transcription 
factor 1, essential for thyroid-specific gene expression47. The selected SNPs are not known to affect CAD/MI other 
than via the relevant exposures (pleiotropy). However, the DIO1 gene associated with FT4 is also associated with 
FT3 and FT3/FT4 ratio57. As such, we cannot exclude the role of other thyroid hormones. SNPs in the ABO gene 
are known to be strongly associated with IHD52, so we presented estimates excluding and including the ABO SNP 
rs657152 for TSH. Sensitivity analyses using a weighted median method and MR Egger with different assump-
tions from inverse variance weighting (IVW) also provided consistent results for most associations, which adds 
some strength. Second, use of separate samples means that we cannot test the possibility that the SNPs for TSH 
and FT4 have different effects on CAD/MI at different levels of the exposures or at different ages. Generally causal 
factors are consistent, although interventions may not always have consistent effects, because the distribution 
of causal factors may vary across populations. Third, population stratification might affect the MR estimates. 
However, the genetic associations with TSH, FT4 and TPOAb positivity and with CAD/MI and CVD risk factors 
are all from studies conducted in Caucasians, largely of European descent, with genomic control50, 52, 58–67. Fourth, 
our study was limited to Caucasians and might not apply to other populations. However, the effects of causal 
factors are not expected to vary by setting68. The effect of TSH-lowering intervention on lipid profile is consistent 
across countries36–38. Fifth, the influence of genetic determinants might be damped or buffered by compensatory 
Figure 1. SNP specific and total associations per standard deviation (SD) thyroid-stimulating hormone 
(TSH), free thyroxine (FT4) and thyroid peroxidase antibody (TPOAb) positivity with CAD/MI, CAD 
and MI, obtained from separate sample instrumental variable analysis in CARDIoGRAMplusC4D52, 58 and 
CARDIoGRAMplusC4D 1000 Genomes50.
www.nature.com/scientificreports/
5Scientific RepoRts | 7: 8515  | DOI:10.1038/s41598-017-07592-z
developmental processes, i.e., canalization45. However, the GWAS for all exposures were conducted in people with 
normal thyroid function47. Sixth, we cannot determine the clinical significance of these small effect sizes, because 
MR estimates should be interpreted as hypothesis testing for causation, rather than indicating the exact size of 
causal effects69. However, small effects that may not be clinically significant may still be an important determinant 
of population health. Seventh, blood pressure was not included in the study, because the publicly available data 
providing the genetic association with blood pressure, i.e., the International Consortium for Blood pressure70, 71, 
does not give the direction of association. Eighth, associations with WHR in men and with 2 hour glucose in men 
Figure 2. SNP specific and total associations per standard deviation (SD) thyroid-stimulating hormone 
(TSH) with low-density lipoprotein (LDL)-cholesterol (inverse normal transformed effect size), high-density 
lipoprotein (HDL)-cholesterol (inverse normal transformed effect size), triglycerides (inverse normal 
transformed effect size) and diabetes, obtained from separate sample instrumental variable analysis in the 
Global Lipids Genetics Consortium Results59 and DIAGRAM60.
Figure 3. SNP specific and total associations per standard deviation (SD) free thyroxine (FT4) with low-
density lipoprotein (LDL)-cholesterol (inverse normal transformed effect size), high-density lipoprotein 
(HDL)-cholesterol (inverse normal transformed effect size), triglycerides (inverse normal transformed effect 
size) and diabetes, obtained from separate sample instrumental variable analysis in the Global Lipids Genetics 
Consortium Results59 and DIAGRAM60.
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and women were null after Bonferroni correction. However, most outcomes were expected to have no associa-
tion with TSH, so the value of adjusting for multiple comparisons is moot. Given the limited SNPs available for 
sex-specific analyses of adiposity, the associations with adiposity need to be replicated in other MR studies using 
different genetic determinants. Ninth, MR requires large sample sizes, because the genetic predictors identified in 
GWAS only explain a small proportion of the variance in thyroid function47. The genetic architecture for thyroid 
function is also unclear, and GWAS based on statistical analysis may not identify all functionally relevant genetic 
variants. A large proportion of the heritability in thyroid function is still unexplained49. There were also a limited 
number of SNPs for FT4 and TPOAb positivity, and for TSH in sex-specific analyses. Tenth, non-collapsibility 
and ascertainment bias are often encountered in MR when using a binary outcome from case-control studies, and 
the estimate from MR Egger provides an approximation72. Lastly, we could not assess whether the effects on IHD 
Figure 4. SNP specific and total associations of thyroid peroxidase antibody (TPOAb) positivity with low-
density lipoprotein (LDL)-cholesterol (inverse normal transformed effect size), high-density lipoprotein 
(HDL)-cholesterol (inverse normal transformed effect size), triglycerides (inverse normal transformed effect 
size) and diabetes, obtained from separate sample instrumental variable analysis in the Global Lipids Genetics 
Consortium Results59 and DIAGRAM60.
Figure 5. SNP specific and total associations per standard deviation (SD) thyroid-stimulating hormone (TSH) 
with body mass index (BMI) in men (inverse normal standard transformed) and in women (inverse normal 
standard transformed), waist-hip ratio (WHR) in men (inverse normal standard transformed) and in women 
(inverse normal standard transformed), obtained from separate sample instrumental variable analysis in 
GIANT64, 65.
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and most CVD risk factors vary by sex. Sex-specific associations with IHD, lipids, diabetes and glucose metabo-
lism are unavailable. As such our estimates for these outcomes are likely to be conservative as some associations 
could be sex-specific.
Our study is inconsistent with some observational studies showing TSH associated with higher risk of CVD 
events34. The null associations of TSH and FT4 with most CVD risk factors are also inconsistent with some studies 
showing higher TSH and lower FT4 associated with an unhealthier CVD risk profile24–27. However, observational 
studies are open to residual confounding and reverse causality, making them difficult to use as a basis for action73. 
Moreover, the hypothalamic–pituitary–thyroid axis interacts with the hypothalamic–pituitary–gonadal axis16, 
and might be affected by diet74, so separating their roles is challenging in observational studies. The association 
of FT4 with lower LDL-cholesterol is consistent with some RCTs showing beneficial effect of levothyroxine, a 
manufactured form of thyroxine, on LDL-cholesterol36–38. The Coronary Drug Project found a detrimental effect 
of dextrothyroxine on CVD40. However, given the pleiotropic effects of dextrothyroxine75, whether the effect is 
mediated by lowering TSH is unclear. The effect of levothyroxine on CVD, is being examined in trials but results 
are unavailable43, 44.
Several explanations might exist for the largely null associations of TSH, FT4 and TPOAb positivity with IHD 
and CVD risk factors. First, the genetic variants may not be determinants of these exposures. The SNPs are from 
GWAS, which are selected based on statistical correlation rather than biological pathways. The genetic variants 
for TSH and FT4 may also be incomplete; because SNPs in the functionally relevant genes, such as TSHB and 
TSHR, were not identified by GWAS. The GWAS may also be underpowered to detect a convincing correlation 
between TSH and FT4 variants47; only the FOXE gene for TSH is also associated with FT4 (Supplemental Table 1). 
Replication using more comprehensive genetic variants is needed. Second, thyroid hormones might not affect 
IHD, or have little effect on IHD, although they may affect lipid profile. Consistently, several drugs, such as 
estrogen, niacin and fibrates, generally modulate lipids in the desired direction but failed to reduce CVD76. Third, 
given that sex-specific analysis for CAD/MI is not available, we cannot rule out positive estimates in sex-specific 
analyses.
From the perspective of clinical practice, MR could have helped avoid several very expensive late-stage clini-
cal trial failures and might improve prediction of what RCTs will show77. Our study adds to the limited evidence 
concerning the role of TSH, FT4 and TPOAb positivity in CAD/MI and provides little indication that TSH, FT4 
or TPOAb positivity affects the risk of CAD/MI, although we cannot rule out their potential effects on CVD risk 
factors. Our findings do not corroborate thyroid function as targets of intervention for IHD. Replication using 
more comprehensive genetic variants in sex-specific analysis is required.
Conclusions
This novel study provides little indication that TSH, FT4 or TPOAb positivity affects IHD, despite potential 
effects on CVD risk factors. Our findings do not corroborate thyroid function as targets of intervention for IHD. 
Although we cannot completely rule out an effect of thyroid function on IHD, our study suggests other targets of 
intervention should be sought to tackle the leading cause of global morbidity and mortality.
Figure 6. SNP specific and total associations per standard deviation (SD) free thyroxine (FT4) with body 
mass index (BMI) in men (inverse normal standard transformed) and in women (inverse normal standard 
transformed), waist-hip ratio (WHR) in men (inverse normal standard transformed) and in women (inverse 
normal standard transformed), obtained from separate sample instrumental variable analysis in GIANT64, 65.
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Methods
Genetic predictors, i.e., SNPs, for TSH and FT4, were obtained from a large meta-analysis of GWAS (n = 26,420 
for TSH and n = 17,520 for FT4) of European descent from 15 cohorts (mean age 42.5 to 79.0 years old), which 
excluded people taking thyroid medication, with thyroid surgery, or with TSH values outside the normal range 
(TSH > 4.0 mIU/L or TSH < 0.4 mIU/L), with genetic associations adjusted for age, age-squared, and sex47, 
and a large meta-analysis of whole-genome sequence-based analysis (n = 16,335) in healthy individuals of 
European descent from 7 cohorts (mean age 7.5 to 54.1 years old), with genetic associations adjusted for age, 
age-squared, sex and any other cohort-specific variables49. Genetic predictors for TSH were also obtained from 
a large whole-genome sequencing study of the Icelandic population (n = 2,636), mean age 55 years old, with 
genetic associations adjusted for age and sex48. Genetic predictors for TPOAb positivity were obtained from a 
large meta-analysis of GWAS in general population in 18,297 Caucasians from 11 studies (mean age 46.9 to 74.8 
years old), with genetic associations adjusted for age and sex22. Only SNPs strongly (p-value < 5 × 10−8) and solely 
associated with TSH or FT4 were used. Correlations between the selected SNPs, i.e., LD, were checked using a 
comprehensive genetic cross-reference system, Ensembl (http://www.ensembl.org/index.html). Where SNPs were 
highly correlated (r2 > 0.7), the SNP with the larger p-value was discarded. Less strongly correlated SNPS were 
included taking LD into account. Pleiotropy, i.e., associations with CAD/MI other than via the relevant expo-
sures were checked using two comprehensive genetic cross-reference systems, Ensembl (http://www.ensembl.org/
index.html) and MR Catalogue (http://mrcatalogue.medschl.cam.ac.uk/), which provide well-established effects 
of known SNPs in the form of cross-references from SNP to trait/phenotype.
Data on CAD/MI have been contributed by CARDIoGRAMPLUSC4D investigators and downloaded from 
www.CARDIOGRAMPLUSC4D.ORG. CARDIoGRAMplusC4D Metabochip is a large case (n = 63,746)-control 
(n = 130,681) study, largely of European descent, mean age 56.9 years old, with genetic associations adjusted for 
age, sex and study specific covariates58. CARDIOGRAM is a subset of CARDIoGRAMplusC4D with more exten-
sive genotyping52. Genetic associations with CAD/MI were obtained from CARDIoGRAMplusC4D if available; or 
else from CARDIOGRAM. CARDIoGRAMplusC4D 1000 Genomes is a case (n = 60,801)-control (n = 123,504) 
study, 77% of European descent, which partly overlaps with CARDIoGRAMplusC4D Metabochip50. Genetic asso-
ciations with lipids (as inverse normal transformed effect sizes), including HDL-cholesterol, LDL-cholesterol and 
triglycerides, adjusted for age, age2 and sex, were obtained from the Global Lipids Genetics Consortium Results 
(http://csg.sph.umich.edu//abecasis/public/lipids2013/), with 188,577 participants of European descent and 7,898 
participants of non-European descent, mean age 55.2 years old59. Genetic associations with diabetes, adjusted 
for age and sex, were obtained from the DIAbetes Genetics Replication And Meta-analysis (DIAGRAM), http://
diagram-consortium.org/downloads.html, case (n = 34,840)-control (n = 114,981) study, mean age 57.4 years 
old60. Genetic associations, adjusted for age, sex and study-specific covariates, with HbA1c (n = 46,368)61, fasting 
glucose (mmol/L) (n = 108,557)62, 2 hour glucose (mmol/L) adjusted for BMI (n = 42,854)62, log-transformed 
fasting insulin (pmol/L) (n = 108,557)62, β-cell function (log-transformed homeostatic model assessment 
(HOMA-b), n = 46,186)63 and HOMA-insulin resistance (IR) (log-transformed HOMA-IR, n = 46,186)63 were 
obtained from the Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC), http://www.magi-
cinvestigators.org/, of people with no diabetes and of European ancestry. Genetic associations, adjusted for age, 
age2, and study-specific covariates, with inverse standard normal transformed BMI in 152,893 men and 171,977 
women of European ancestry64 and inverse standard normal transformed WHR in 93,480 men and 116,741 
women65, were obtained from the Genetic Investigation of ANthropometric Traits (GIANT), https://www.broa-
dinstitute.org/collaboration/giant/index.php/GIANT_consortium_data_files.
The associations of TSH, FT4 and TPOAb positivity with CAD/MI and CVD risk factors were obtained from 
separate sample instrumental variable (SSIV) using the Wald estimate (the ratio of genetic association with CAD/
MI and with TSH, FT4 and TPOAb positivity).
SNP-specific estimates were then combined using IVW with fixed effects for uncorrelated SNP and weighted 
generalized linear regression for correlated SNPs54. The standard deviation of the ratio was obtained from Fieller’s 
theorem78. The instrument strength is typically represented by the F-statistic72. In the two-sample summary data 
context and with uncorrelated genetic variants, we approximated the F-statistic for each genetic variant using an 
established formula72, and calculated the mean F-statistic for TSH, FT4 and TPOAb positivity. The IVW method 
assumes that all genetic variants are valid instruments72. We also used a weighted median method and MR Egger, 
because we wanted to account for the potential bias from invalid instruments when using multiple genetic vari-
ants as instrument79. The weighted median method provides a consistent estimate of the causal effect even when 
up to 50% of the information contributing to the analysis comes from genetic variants that are invalid instru-
ments80. MR Egger tests for directional pleiotropy, under the assumption that pleiotropic effects of genetic var-
iants are independent of instrumental strength80. To examine potential bias from SNPs which had associations 
with the outcomes other than via these exposures (violation of the exclusion restriction assumption), sensitivity 
analyses including SNPs which had potentially pleiotropic associations with the outcomes were conducted. We 
tested for heterogeneity using Cochran’s Q test, and tested for directional pleiotropy by testing the intercept from 
MR Egger, where a p-value of <0.05 indicates the presence of directional pleiotropy across the genetic variants 
included in the analyses81. To account for multiple comparisons, we also used a Bonferroni correction. All statis-
tical analyses were conducted using R version 3.3.2 (R Foundation for Statistical Computing, Vienna, Austria).
Data availability statement. Data on CAD/MI have been contributed by CARDIoGRAMPLUSC4D 
investigators and downloaded from www.CARDIOGRAMPLUSC4D.ORG. Genetic associations with lipids 
were obtained from the Global Lipids Genetics Consortium Results (http://csg.sph.umich.edu//abecasis/public/
lipids2013/). Genetic associations with diabetes are from the DIAbetes Genetics Replication And Meta-analysis 
(DIAGRAM), http://diagram-consortium.org/downloads.html. Genetic associations with glucose metabolism 
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indicators were obtained from the Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC), 
http://www.magicinvestigators.org/. Genetic associations with inverse standard normal transformed BMI and 
inverse standard normal transformed WHR were obtained from the Genetic Investigation of ANthropometric 
Traits (GIANT), https://www.broadinstitute.org/collaboration/giant/index.php/GIANT_consortium_data_files.
Ethical approval. This analysis of publicly available data does not require ethical approval.
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